STL Index for: Kendall Coleman
Janus Kinase and Tyrosine Kinase Inhibitors in Dermatology: A Review of Their Utilization, Safety Profile and Future Applications
Currently, JAK inhibitors are only FDA approved for dermatologic, rheumatologic, and hematologic conditions. Recent studies show the utility of JAK inhibitors in treating atopic dermatitis, psoriasis, psoriatic arthritis, vitiligo, and alopecia areata.
This review examines the clinical trials of topical diacerein and its role in Epidermolysis Bullosa Simplex. Diacerein cream was recently US FDA-approved in May 2018 for treatment of patients with EBS.
Glycopyrronium tosylate (Qbrexza), a topical anticholinergic therapy, has been shown to be effective in the treatment of primary axillary hyperhidrosis.